UBS Group’s BioNTech BNTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$604K Sell
6,800
-43,800
-87% -$4.5M ﹤0.01% 5948
2025
Q4
$4.82M Hold
50,600
﹤0.01% 4066
2025
Q3
$4.99M Hold
50,600
﹤0.01% 4034
2025
Q2
$5.39M Sell
50,600
-12,600
-20% -$1.27M ﹤0.01% 3796
2025
Q1
$5.75M Sell
63,200
-43,700
-41% -$4.89M ﹤0.01% 3646
2024
Q4
$12.2M Buy
106,900
+15,400
+17% +$1.76M ﹤0.01% 2843
2024
Q3
$10.9M Buy
91,500
+37,400
+69% +$3.44M ﹤0.01% 2285
2024
Q2
$4.35M Sell
54,100
-474,200
-90% -$43.3M ﹤0.01% 3005
2024
Q1
$48.7M Buy
528,300
+390,300
+283% +$37.4M 0.01% 1053
2023
Q4
$14.6M Buy
138,000
+17,000
+14% +$1.71M ﹤0.01% 1819
2023
Q3
$13.1M Buy
+121,000
New +$13.4M ﹤0.01% 1773
2023
Q2
Sell
-25,000
Closed -$3.11M 8950
2023
Q1
$3.11M Sell
25,000
-16,100
-39% -$2.21M ﹤0.01% 2962
2022
Q4
$6.17M Buy
+41,100
New +$6.32M ﹤0.01% 2299
2022
Q2
Sell
-4,100
Closed -$699K 10332
2022
Q1
$699K Sell
4,100
-95,900
-96% -$16.1M ﹤0.01% 4439
2021
Q4
$25.8M Sell
100,000
-300
-0.3% -$82.2K 0.01% 1411
2021
Q3
$27.4M Buy
100,300
+300
+0.3% +$95.3K 0.01% 1256
2021
Q2
$22.4M Hold
100,000
0.01% 1412
2021
Q1
$10.9M Buy
+100,000
New +$10.6M ﹤0.01% 1878

Other funds holding BNTX

UBS Group's BNTX Position: Q1 2026 in Review

UBS Group reduced its BioNTech (BNTX) stake by 0.43% in Q1 2026, selling an estimated $106K and leaving 240,538 shares worth $21.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2519.

UBS Group first reported a position in BNTX in Q4 2019 and has held it in 26 quarters since. The position peaked at $95.4M in Q3 2021. 272 funds tracked by Wall St. Rank hold BNTX as of Q1 2026.

  • UBS Group held 240,538 shares of BioNTech worth $21.4M as of Q1 2026.
  • UBS Group sold 1,035 BioNTech shares in Q1 2026, an estimated $106K.
  • BioNTech made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #2519 holding.
  • UBS Group first reported a position in BioNTech in Q4 2019 and has held it in 26 quarters since.
  • UBS Group's BioNTech position peaked at $95.4M in Q3 2021.
  • 272 funds tracked by Wall St. Rank held BioNTech as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.